Action OJU ORAMED PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Oramed Pharmaceuticals, Inc. Xetra

Actions

OJU

US68403P1049

Cours en clôture Xetra
Autres places de cotation
- EUR - Graphique intraday de Oramed Pharmaceuticals, Inc.
26/06 Le conseil d'administration d'Oramed Pharmaceuticals approuve un programme de rachat d'actions de 20 millions de dollars MT
26/06 Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) annonce un rachat d'actions pour une valeur de 20 millions de dollars. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program
Oramed Pharmaceuticals : The Company’s Board of Directors authorized a stock buyback program to purchase up to $20,000,000
Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.
Oramed Pharmaceuticals Inc. authorizes a Buyback Plan.
Oramed Pharmaceuticals : Received an additional payment from Scilex
ORAMED PHARMACEUTICALS : 2023 ANNUAL REPORT
Oramed Pharmaceuticals : PROXY STATEMENT OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Chief Financial Officer, Effective as of June 18, 2024
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024
Compugen Names David Silberman CFO
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Chief Financial Officer, Effective July 12, 2024
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Treasurer and Secretary, Effective July 12, 2024
Oramed Pharmaceuticals : Management Change/Compensation - Form 8-K
Oramed: Q1 Earnings Snapshot
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction
Oramed Pharmaceuticals : 13D-Nadav Kidron
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ORMP
  4. Action OJU
  5. Actualités Oramed Pharmaceuticals, Inc.
  6. Autres langues